AlphAIalphai — Financial news for AI agents
fool.comAUG 193 min read$MIST

Milestone (MIST) Q2 2026 Earnings Call Transcript

Milestone Pharmaceuticals (MIST) reported Q2 2026 earnings, with product revenue of $559,000 and a net loss of $28.6 million. The company saw a fourfold increase in prescriptions and 50% commercial insurance coverage for CARDAMYST. Management expects cash runway into 2H 2027 and anticipates Medicare coverage in 2027. The Phase III trial for AFib-RVR is underway, targeting a larger patient population.

Original reporting
fool.com
Published Aug 19, 2026, 2:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 2:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Milestone (MIST) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$MISTNeutralMed
01

Why it matters

The earnings release provides fresh financial metrics and updates on commercial coverage and pipeline progress, offering traders new data points for valuation.

02

Market read

The report informs pricing and risk assessment for MIST and may affect peer biotech stocks in the cardiac therapeutic space.

03

What to watch

Potential reimbursement improvements and upcoming EMA decision could unlock significant upside.

Relevance 7/10Novelty 7/10Timing: post‑earnings release

Background

Milestone Pharmaceuticals reported its Q2 2026 results, marking the first full quarter of commercial sales for its CARDAMYST therapy.

Company-level read

Ticker impact

$MISTNeutralMedium confidence
Context

Q2 2026 earnings call disclosed product revenue of $559k, net loss of $28.6M, cash runway into H2 2027, and upcoming Phase III trial data.

Expected impact

Limited upside unless Phase III data or guidance improves expectations.

Evidence & confidence

The company shows revenue growth and cash sufficiency, but widening loss and high SG&A suggest modest short‑term impact.

Market effects

Sector

Highlights commercial rollout progress for niche cardiac therapies, may influence peer biotech valuations.

Regional

US biotech investors may reassess cash‑runway timelines for similar small‑cap firms.

Global

Limited; primarily relevant to US biotech sector.

Counterpoint

What could challenge this read

Despite revenue growth, the widening net loss and high cash burn could pressure the stock if guidance remains weak.

Key entities

  • company
    Milestone Pharmaceuticals Inc.

    Developer of CARDAMYST for PSVT and AFib‑RVR.

Read at source← All news

Related articles

AUG 21
$MISTMed

Milestone Pharmaceuticals stock gains on Phase 3 AFib trial

Milestone Pharmaceuticals (MIST) shares rose 3.9% after enrolling the first patient in its Phase 3 ReVeRA-301 trial for etripamil in treating AFib-RVR. The trial evaluates the same 70 mg dose approved for PSVT. The study aims to enroll 150 patients, with primary and secondary endpoints focused on ventricular rate reduction and symptom improvement. Milestone seeks FDA approval for home use. AFib affects 6 million U.S. patients, with projected economic costs rising to $174.8 billion by 2050, accor

investing.com2 min
AUG 13
$MISTMed

Milestone Pharmaceuticals Q2 Earnings Call Highlights

Milestone Pharmaceuticals (NASDAQ:MIST) reported Q2 product revenue of $0.6M versus none a year earlier, and a net loss of $28.6M ($0.21/share). Management said CARDAMYST prescriber uptake and payer coverage improved, with coverage at about 25% of commercially insured lives and plans to expand. Milestone also started registrational enrollment for ReVeRA-301 etripamil in AFib-RVR.

yahoo.com6 min
AUG 12
$MISTMedAI 8/10

Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals (Nasdaq: MIST) reported Q2 2026 results and a corporate update. It said CARDAMYST (etripamil) prescriptions and coverage expanded, with cash, cash equivalents and short-term investments of $170.6 million as of June 30, 2026. The Phase 3 ReVeRA-301 AFib-RVR trial opened, and EMA/China reviews are ongoing. Q2 net loss was $28.6 million.

finanznachrichten.de7 min
AUG 12
$MISTMed

Milestone Pharmaceuticals Inc. (MIST): Results of Operations and Financial Condition

Milestone Pharmaceuticals Inc. (MIST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2614433d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage

SEC EDGAR 8-K6 min
AUG 23
$PGMedAI 8/10

3 Dividend Stocks to Buy Before August Ends and Hold for Life

Procter & Gamble (PG) reported fiscal 2026 earnings with $6.89 EPS and $87.03B revenue, announcing a $10B+ capital return plan. PepsiCo (PEP) posted Q2 2026 revenue of $24.18B, highlighting strong international growth. Coca-Cola (KO) saw Q2 2026 volume growth of 5% and raised full-year guidance, benefiting from World Cup momentum.

247wallst.com3 min
Milestone (MIST) Q2 2026 Earnings Call Transcript — alphai